2021
Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis
Ward Z, Stone J, Bishop C, Ivakin V, Eritsyan K, Deryabina A, Low A, Cepeda J, Kelly SL, Heimer R, Cook R, Altice FL, Litz T, Terlikbayeva A, El-Bassel N, Havarkov D, Fisenka A, Boshnakova A, Klepikov A, Saliuk T, Deshko T, Vickerman P. Costs and impact on HIV transmission of a switch from a criminalisation to a public health approach to injecting drug use in eastern Europe and central Asia: a modelling analysis. The Lancet HIV 2021, 9: e42-e53. PMID: 34895484, PMCID: PMC8762142, DOI: 10.1016/s2352-3018(21)00274-5.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyAgonist therapyAntiretroviral therapyPublic health approachHIV transmissionDrug useDynamic HIV transmission modelHealth approachIncremental cost-effectiveness ratioHIV transmission modelNational InstituteCost-effectiveness ratioCountry-specific costsHIV incidenceUNAIDS 90US National InstitutesART coverageWHO targetPWIDTherapyPay thresholdsInfectious diseasesCost savingsDrug abuseIncremental cost
2015
Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States
Song DL, Altice FL, Copenhaver MM, Long EF. Cost-Effectiveness Analysis of Brief and Expanded Evidence-Based Risk Reduction Interventions for HIV-Infected People Who Inject Drugs in the United States. PLOS ONE 2015, 10: e0116694. PMID: 25658949, PMCID: PMC4320073, DOI: 10.1371/journal.pone.0116694.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsOpioid substitution therapyHIV infectionHIV incidenceHIV prevalenceEvidence-based risk reduction interventionDynamic HIV transmission modelHolistic Health Recovery ProgramBehavioral HIV prevention interventionsFuture HIV incidenceTotal medical costsHIV transmission modelHIV prevention interventionsGeneral adult populationRisk reduction interventionsCost-effectiveness analysisSubstitution therapySexual transmissionHIV programsPrevention interventionsMedical costsTreatment settingsLife yearsReduction interventionsUS population